(Sharecast News) - Analytics company Ixico has inked a supply agreement with Life Molecular Imaging that will see it supply that latter's Neuraceq Amyloid PET tracer for use in pharma-sponsored clinical trials.
As a result of its agreement with LMI, Ixico will further extend its service offering to provide Neuraceq, a diagnostic agent that improves early detection and characterization of chronic and life-threatening diseases, to complement its "well-established PET imaging services and image data analytics".
The AIM-listed group states that LMI's provision of tracer supply to imaging centres together with its oversight of imaging will "minimise the operational burden" to trial sponsors and will improve patient experience, ultimately driving study eligibility and efficacy endpoint delivery.
Chief executive Giulio Cerroni said: "Ixico is committed to the continuous development of our suite of AI enabled analytics and reader services for innovative new PET tracers and so we are delighted to be partnering with LMI to improve access and supply to LMI's Neuraceq. We anticipate that the extension of this Neuraceq tracer co-ordination service from Ixico will be very well received by our global biopharmaceutical sponsors."
As of 0930 BST, Ixico shares were down 0.64% at 8.69p.
Reporting by Iain Gilbert at Sharecast.com
Ixico (IXI)